1. Scrip

Helixmith Facing Engensis Challenges After Disappointing First Phase III Data

 
• By Jung Won Shin

Helixmith delays making conclusions on disappointing first top-line data from lead US Phase III study of plasmid DNA therapeutic Engensis, citing unexpected pharmacokinetic results in the placebo and treatment groups. The South Korean biotech vows to improve strategy for upcoming trials, but much may hinge on their success.

Signpost
Helixmith Eyes Strategies For Engensis Trial Success • Source: Shutterstock

Helixmith has found serious flaws in pharmacokinetic data from the first Phase III trial with its lead product Engensis (VM202) and has delayed making conclusions based on what were the first top-line results from a US study.

During a review of the recently completed Phase III study of Engensis versus placebo in 500 patients with painful diabetic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gene Therapies

More from Advanced Therapies

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 
• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?